Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bausch + Lomb Corporation Common Shares (NY:BLCO)

16.73 -0.15 (-0.89%)
Streaming Delayed Price Updated: 12:42 PM EDT, Apr 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 73,768
Open 16.83
Bid (Size) 16.73 (300)
Ask (Size) 16.76 (100)
Prev. Close 16.88
Today's Range 16.71 - 16.99
52wk Range 10.45 - 18.91
Shares Outstanding 353,800,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Bausch + Lomb Reports Nearly 725,000 Pounds of Contact Lens, Lens Care and Eye Care Materials Collected and Recycled Through ONE By ONE Recycling Program
From Bausch + Lomb Corporation
Via Business Wire
News headline image
3 Cash-Burning Stocks We Keep Off Our Radar
Companies that burn cash at a rapid pace can run into serious trouble if they fail to secure funding. Without a clear path to profitability, these businesses... 
Via StockStory
Topics Bankruptcy

Performance

YTD
+0.9%
+0.9%
1 Month
+1.5%
+1.5%
3 Month
-3.4%
-3.4%
6 Month
+11.8%
+11.8%
1 Year
+40.2%
+40.2%

More News

Read More
News headline image
1 Healthcare Stock with Solid Fundamentals and 2 We Brush Off
Via StockStory
News headline image
Bausch + Lomb Launches Preloaded enVista Envy™ Full Range of Vision Intraocular Lenses in Europe
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Corp (NYSE:BLCO) Reports Mixed Q4 2025 Results: Revenue Beat, EPS Miss ↗
Via Chartmill
News headline image
Bausch + Lomb Announces New Scientific Data, Educational Events at the American Society of Cataract and Refractive Surgery Annual Meeting
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Q4 Rundown: Bausch + Lomb (NYSE:BLCO) Vs Other Medical Devices & Supplies - Specialty Stocks
Via StockStory
News headline image
Bausch + Lomb Will Release First-Quarter 2026 Financial Results on April 29
From Bausch + Lomb Corporation
Via Business Wire
News headline image
3 Reasons BLCO is Risky and 1 Stock to Buy Instead
Via StockStory
Topics Bankruptcy
News headline image
A Bausch + Lomb Director Just Bought $77,000 in Stock. That's Only Half the Story ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Bausch + Lomb Announces Positive 24-Month U.S. Data on the ELIOS™ System for Treatment of Glaucoma
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Billboard Giant Posts $1.6 Billion Revenue as $20.5 Million Bet Makes It a Top Portfolio Holding ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Eye Care Giant Posts $5.1 Billion in Revenue as One Investor Builds Major Position ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Bausch + Lomb Launches R&D “Teach-in” Webinar Series
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Integra LifeSciences, GE HealthCare, Bausch + Lomb, ICU Medical, and Universal Health Services Shares Are Falling, What You Need To Know
Via StockStory
Topics Earnings Economy
News headline image
2 Profitable Stocks Worth Investigating and 1 We Ignore
Via StockStory
News headline image
Viatris (VTRS): From Debt-Laden Merger to Specialty Powerhouse—A 2026 Research Deep Dive
Via Finterra
Topics Economy Initial Public Offering Retirement
News headline image
5 Revealing Analyst Questions From Bausch + Lomb’s Q4 Earnings Call
Via StockStory
Topics Earnings
News headline image
Ophthalmology and Therapy Publishes Findings Showing Lifestyle-Driven Rise in Ocular Redness and Differentiated Role of LUMIFY®
From Bausch + Lomb Corporation
Via Business Wire
News headline image
3 Small-Cap Stocks We Steer Clear Of
Via StockStory
News headline image
BLCO Q4 2025 Deep Dive: Dry Eye and Product Innovation Propel Growth, Margin Expansion in Focus
Via StockStory
News headline image
Bausch + Lomb’s (NYSE:BLCO) Q4 CY2025: Beats On Revenue
Via StockStory
News headline image
Bausch + Lomb Announces Fourth-Quarter and Full-Year 2025 Results, Provides 2026 Guidance
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb (BLCO) Q4 Earnings: What To Expect
Via StockStory
Topics World Trade
News headline image
3 Reasons to Sell BLCO and 1 Stock to Buy Instead
Via StockStory
Topics Bankruptcy Stocks

Frequently Asked Questions

Is Bausch + Lomb Corporation Common Shares publicly traded?
Yes, Bausch + Lomb Corporation Common Shares is publicly traded.
What exchange does Bausch + Lomb Corporation Common Shares trade on?
Bausch + Lomb Corporation Common Shares trades on the New York Stock Exchange
What is the ticker symbol for Bausch + Lomb Corporation Common Shares?
The ticker symbol for Bausch + Lomb Corporation Common Shares is BLCO on the New York Stock Exchange
What is the current price of Bausch + Lomb Corporation Common Shares?
The current price of Bausch + Lomb Corporation Common Shares is 16.73
When was Bausch + Lomb Corporation Common Shares last traded?
The last trade of Bausch + Lomb Corporation Common Shares was at 04/16/26 12:42 PM ET
What is the market capitalization of Bausch + Lomb Corporation Common Shares?
The market capitalization of Bausch + Lomb Corporation Common Shares is 5.92B
How many shares of Bausch + Lomb Corporation Common Shares are outstanding?
Bausch + Lomb Corporation Common Shares has 6B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.